OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock

Sep 11, 2018

OPKO Comments on SEC Complaint

Sep 7, 2018

OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients

Sep 4, 2018

OPKO Health’s BioReference Laboratories to Participate in the National Cancer Institute NCI-MATCH (Molecular Analysis for Therapy Choice) Phase II Clinical Trial

Aug 28, 2018

OPKO Health Reports Second Quarter 2018 Financial Results

Aug 7, 2018

OPKO Health Completes Enrollment in Global Phase 3 Study of Somatrogon (hGH-CTP) in Growth Hormone Deficient Children

Aug 3, 2018

OPKO Health to Announce Second Quarter 2018 Financial Results on August 7, 2018

Aug 2, 2018

OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada

Jul 16, 2018

GeneDx Announces Completion of 100,000 Exome Sequences

Jun 12, 2018

OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity

Jun 11, 2018